AMITYVILLE, N.Y.--(BUSINESS WIRE)--Hi-Tech Pharmacal Co., Inc. (NASDAQ:HITK) announced today that it entered into a settlement and release agreement regarding the patent infringement suit brought by MedPointe Pharmaceuticals related to Hi-Tech’s generic version of Tussi-12® DS, covered by the claims of the asserted patent. Under the terms of the agreement Hi-Tech will immediately cease distribution of its generic version of Tussi-12® DS and pay MedPointe $2.5 million. The agreement also resolves various claims brought by Hi-Tech against MedPointe and JFC Technologies, Inc. in a separate lawsuit. Under the terms of the agreement, MedPointe will transfer to Hi-Tech its Vosol® and Vosol® HC brands, and the related New Drug Applications.
